Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 18Colorectal Neoplasms 17Stomach Neoplasms 10Colonic Neoplasms 7Gastrointestinal Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Recurrence 1Rcctal Cancer 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Locally Advanced Colorectal Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adebrelimab (SHR-1316) 1

Interventions

Oxaliplatin 3Radiotherapy 2Folfox protocol 2Fluorouracil 2Capecitabine 2Bevacizumab 2Artesunate 2camrelizumab 1apatinib 1alectinib 1XELOX 1Trastuzumab 1Ocoxin 1Leucovorin 1Irinotecan 1Drug Therapy 1Chemoradiotherapy 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Neoplasms × XELOX × Clear all
NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Fudan University

Phase 2 Unknown
77 enrolled
Gastrointestinal

Intestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡